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INTRODUCTION 
Insomnia is a disorder defined by dissatisfaction with the 
quantity or quality of sleep that occurs more than three nights 
per week for at least 3 months, and includes clinically significant 
distress in important areas of functioning. Sleep dissatisfaction is 
characterized by difficulty in initiating or maintaining sleep, or 
early-morning awakening with an inability to return to sleep de-
spite adequate opportunity. Overall, 45–75% of insomnia pa-
tients are chronic sufferers [1] and there is a relatively high re-
lapse rate after remission (12–33%) [2]. 
Increasing insomnia prevalence is a global problem [3,4]. In 
South Korea, a statistical analysis of Korea Health Insurance 
Claims data showed a 34% increase in the number of patients 
with insomnia between 2012 and 2016 [5]. As the prevalence of 
insomnia increases, so does the demand for treatment. The re-
port estimated that the global market for sleep-related drugs will 
grow at an average annual rate of 5.2% by 2026 [6].
Cognitive behavioral therapy, the first-line treatment for in-
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somnia, is also growing in popularity. Only 30 years have passed 
since cognitive behavioral therapy for insomnia (CBTi) became 
the predominant first-line treatment for insomnia. Fewer than 
10 papers in PubMed discussed CBTi in the early 2000s, but by 
2019, there were 119 papers on that subject in that year alone. 
Despite the explosive interest, widespread use of CBTi is limited 
by accessibility and cost. Internet-delivered digital CBTi (dCBTi) 
was introduced in 2004 [7] and offers an alternative to meet 
growing demand and poor treatment accessibility. This paper 
discusses the history of CBTi as a first-line treatment for insom-
nia, the current status and limitations of CBTi, the efficacy of 
dCBTi as an alternative, and the future of dCBTi in pioneering 
digital therapeutics.
HOW DID CBTi BECOME THE 
PREDOMINANT TREATMENT FOR 
INSOMNIA?
Muscle relaxation is the beginning of non-pharmacological 
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insomnia treatment. Progressive relaxation therapy was first de-
veloped by Jacobsen [8] in the 1930s and is effective for insomnia 
patients. Progressive muscle relaxation therapy reduces muscle 
tension and stops racing thoughts that affect sleep [9]. In subjec-
tive reporting, muscle relaxation therapy reduces sleep onset la-
tency and increases total sleep time [10]. The first clinical study 
of insomnia treatment using relaxation therapy was published in 
the 1960s [11]. In the 1970s, Bootzin’s stimulus control therapy 
for insomnia was introduced [12] as the first non-pharmacologi-
cal treatment specifically developed for insomnia. Stimulus con-
trol therapy for insomnia is based on learning theory related to 
sleep, which is based on the assumptions that external or psy-
chological factors that make it hard to fall asleep act as stimuli. 
These stimuli, which include bedroom and bed environments, 
may illicit stressful and fearful feelings that reinforce the difficul-
ty of falling asleep. Stimulus control therapy develops a coherent 
sleep-wake pattern by reinforcing beds and bedrooms with con-
ditioned sleep stimuli and dissociating conditioned stimuli with 
behaviors that are incompatible with sleep. Stimulus control 
therapy consists of the following guidelines: 1) sleep only when 
you are sleepy; 2) do not use your bed for anything other than 
sleep and sexual activity. Do not read, watch television, eat, or 
worry in bed; 3) if you cannot sleep, get up and go to another 
room. Stay up as long as you want and go back to your bedroom. 
Do not lie in bed for more than 10 minutes without falling 
asleep; 4) if you still cannot sleep, repeat the previous steps; 5) 
wake up at the same time each morning, no matter how much 
you slept. This helps establish a consistent sleep rhythm; and 6) 
do not take naps. 
Sleep hygiene, now a well-known concept, was first introduced 
in 1977 by Hauri [13]. To promote good sleep, most doctors edu-
cate their patients about sleep hygiene, which includes: 1) going 
to bed at the same time and waking up at the same time; 2) 
maintaining a pleasant sleep environment; 3) reducing use of 
sleep-affecting substances, such as alcohol, coffee, and tobacco; 
and 4) exercising. These principles of sleep hygiene are the key 
elements of CBTi.
Sleep restriction therapy, developed around the same time as 
sleep hygiene, is also an important component of CBTi [14]. Ac-
cording to sleep restriction therapy theory, patients with insom-
nia spend too much time trying to sleep, which causes wakeful-
ness, fragmented sleep, and variability in sleep and awake timing. 
Limiting sleep time and establishing a consistent sleep schedule 
is key to sleep restriction therapy. The therapist prescribes a sleep 
schedule based on a two-week sleep diary. Patients with insom-
nia often underestimate sleeping hours, so their sleeping time is 
generally less than what is actually needed. Partial sleep depriva-
tion is thus induced, which increases homeostatic sleep drive 
and strengthens sleep the following night [14]. 
Spielman’s 3P model, which best conceptualizes the mecha-
nism by which insomnia becomes chronic, was published in 
1986 [15]. The 3P model describes the mechanism of chronic in-
somnia on the basis of predisposing factors, precipitating cir-
cumstances, and perpetuating factors. Predisposing factors, in-
cluding hyperarousal traits and a family history of insomnia, 
increase vulnerability to insomnia. Precipitating factors for acute 
insomnia are stressors that negatively affect sleep, such as illness, 
the burden of work or school, and interpersonal conflict. Perpet-
uating factors, such as worry about not being able to sleep, rumi-
nation, and behaviors such as waiting long hours in bed to sleep, 
irregular sleep schedules, naps, and activities in bed other than 
sleeping, cause acute insomnia to become chronic. Persistent in-
somnia is a vicious cycle in which maladaptive behavior and 
cognition increase over time, in turn increasing cognitive hyper-
arousal and preventing sleep even more. Maladaptive behaviors, 
dysfunctional thoughts, and excessive cognitive arousal all con-
tribute to the mechanism of chronic insomnia. The goal of mod-
ifying these factors is to therapeutically influence circadian 
rhythm and sleep homeostatic processes.
Morin [16] developed a cognitive therapy for insomnia based 
on Beck’s cognitive therapy for depression [17]. This insomnia 
therapy restructures cognition by focusing on dysfunctional atti-
tudes about sleep, including unrealistic expectations of sleep, a 
false perception of the causes and consequences of insomnia, 
and a false belief in behaviors that improve sleep. A few years af-
ter the introduction of Morin’s therapy, Harvey [18] proposed a 
new cognitive therapy to address five main cognitive processes 
that sustain insomnia: worry, selective attention and monitoring 
of sleep-related threats, misunderstandings about sleep and day-
time problems, unhelpful beliefs about sleep, and unproductive 
safety behaviors. Harvey’s cognitive therapy is different from the 
other therapies because it includes daytime thoughts and behav-
iors into the treatment focus.
A meta-analysis of CBTi effects was first published in 1994 [19]. 
The report included that conventional CBTi is a multicomponent 
intervention program consisting of: 1) a behavioral component, 
including stimulus control therapy, sleep restriction therapy, and 
muscle relaxation; 2) a cognitive component; and 3) an educa-
tional component focused on sleep hygiene. Therapy usually lasts 
4 to 8 weeks, but can be as long as 16 weeks. Face-to-face sessions 
with a therapist are provided individually or in groups of up to 
eight people. In an analysis of 59 clinical trials, the average effect 
size was 0.88 for sleep onset latency and 0.65 for awake time after 
sleep onset, showing that CBTi is effective for easing difficulties in 
sleep initiation and maintenance. A meta-analysis of 21 prospec-
tive studies in the early 2000s showed that the short-term effect of 
CBTi on overall sleep-related variables was comparable to that of 
pharmacological treatment, and was also more effective at im-
proving sleep onset latency. Stimulus control therapy and sleep 
restriction therapy were the most effective treatments, whereas 
sleep hygiene education was not effective when used alone [20]. 
Building on this evidence, the American Academy of Sleep Medi-
cine published a systematic review of 48 clinical trials that includ-
ed recommendations and supporting evidence for CBTi [21], fol-
lowed by a review of 37 additional studies [22]. Both analyses 
indicated that CBTi was effective in easing difficulties in sleep ini-
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tiation and maintenance, and remained effective for 6–24 months 
after treatment.
CBTi IN THE 21St CENTURY
No studies have shown the duration of CBTi effects or wheth-
er CBTi is effective as a maintenance therapy, although a 2-year 
follow-up study showed that use of sleeping pills decreased in a 
CBTi group compared to control insomnia patients [23]. Morin 
et al. [24] reported that CBTi is effective for treating insomnia, 
whether given alone or in combination with medication. Despite 
showing that CBTi effects were maintained for up to 24 months, 
the paper did not find that CBTi was beneficial as a maintenance 
therapy. This finding was also supported by a comparison of 
2-year treatment outcomes for one-time CBTi versus 6 months 
of monthly CBT sessions in 160 chronic insomnia patients [25]. 
There were many studies on cognitive behavioral therapy for 
secondary insomnia in the early 2000s. Secondary insomnia re-
fers to insomnia associated with psychiatric illness or non-psychi-
atric medical illness (pain, cancer, etc.). With the 2013 publication 
of the Diagnostic and Statistical Manual of Mental Disorders, 5th 
edition (DSM-5) [1], primary and secondary insomnia are no 
longer distinguished, but many studies have examined the effects 
of CBTi on comorbid conditions and insomnia in patients with 
psychiatric or medical comorbidities. 
Evaluating the use of CBTi for concomitant psychiatric disor-
ders has often targeted depression and post-traumatic stress dis-
order (PTSD). Either CBTi alone or CBTi with conventional de-
pression treatment are equally effective in improving insomnia 
and depressive symptoms [26,27]. Taylor et al. [27] provided 
CBTi as a single treatment to depressed patients, finding that 
87.5% of study participants normalized their depression scores 
and 100% reported normalized sleep. However, this study had 
only 10 participants and did not include patients with major de-
pression. Manber et al. [26] reported 61.5% remission in major 
depressive disorders for participants who received a combination 
of escitalopram and CBTi, compared to 33.3% remission in par-
ticipants who received escitalopram combined with a control in-
somnia therapy. 
These studies are important because insomnia is a risk factor 
for depression relapse [28]. In cases of insomnia that persist for 
more than a year, the depression relapse risk is 16 times higher 
[29]. In this context, there is a great need to study the potential of 
CBTi to prevent depression relapse in patients who still have in-
somnia symptoms. One study showed that internet-delivered 
dCBTi improves both depression and insomnia symptoms, but 
no studies have reported a preventive effect for depression re-
lapse [30]. Another study showed that providing CBTi along 
with behavioral therapy for trauma in patients with PTSD 
proved effective for improving both sleep efficiency (Cohen’s 
d=1.01) and sleep onset latency (Cohen’s d=0.89) [31]. 
CBTi is effective for treating insomnia with psychiatric or 
medical comorbidities. Insomnia has a 20% to 80% comorbidity 
with chronic medical illness [32]. Chronic pain and some thera-
peutic drugs can also interfere with sleep [33,34]. Pain and fa-
tigue, which are common in chronic conditions, prevent patients 
from getting out of bed when they cannot sleep, which is the 
main recommendation for stimulation control therapy. Never-
theless, clinical trials have shown that CBTi is an effective insom-
nia treatment even for patients with chronic pain [35]. CBTi is 
also effective for insomnia symptoms associated with cancer and 
human immunodeficiency virus infection [36,37].
The many successful results of CBTi have led to its recommen-
dation as the first-line treatment option for insomnia in nearly 
all guidelines [38-40]. But despite these successes, there are still 
many challenges for CBTi. The successful reports of CBTi have 
all been achieved by face-to-face therapy. Regardless of group or 
individual treatment, therapists check sleep diaries, provide feed-
back, and prescribe sleep schedules individually, which is time-
consuming and costly. Moreover, lack of well-trained therapists 
specialized in CBTi is the biggest barrier to providing CBTi to 
many patients. These challenges are nearly insurmountable for 
patients living in rural areas with low access to medical institu-
tions and older adults burdened by the difficulty of clinic visits, 
yet having the highest prevalence and severity of insomnia [41]. 
Thus, CBTi is not accessible to all individuals with insomnia.
To address these limitations, there has been growing interest 
in implementing CBTi using non-professional primary health-
care providers [42]. A six-week group CBTi trial for 139 insom-
nia patients, in which care was provided by primary care nurses, 
showed that sleep onset latency and wakefulness during the 
night were significantly reduced in the treatment group. The 
same research group showed favorable effects from five sessions 
of CBTi offered by primary care nurses for 201 people with in-
somnia [43]. However, these two studies cannot be applied to 
secondary insomnia because both studies excluded patients with 
comorbidity diagnosis. 
Another limitation of CBTi is the difficulty of providing thera-
py to a large number of patients, because CBTi is only provided 
to 4–6 people at a time. In this context, self-help methods have 
also been evaluated as an alternative to conventional face-to-face 
CBTi. Self-help treatments are defined as standardized psycho-
logical treatments that can be independently conducted by the 
patients themselves. A meta-analysis included 10 studies of self-
help CBTi implemented through a variety of methods, including 
books, internet, and audiotape. The analysis found a mild to 
moderate effect on sleep-related variables, including sleep effi-
ciency (d=0.42), sleep onset latency (d=0.29), wake time after 
sleep onset (d=0.44), and sleep quality (d=0.33). However, sub-
group analysis of studies with patients who had psychiatric co-
morbidities found that the mean effect size fell below 0.2, and 
that there was a significant publication bias [44]. The implemen-
tation of CBTi by primary healthcare providers or self-help 
methods is still limited by the difficulty of obtaining adequate 
feedback, coverage, and accessibility. 
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THE EMERGENCE OF INTERNET-
DELIVERED dCBTi AS AN 
ALTERNATIVE TO CBTi
The limitations of CBTi, as discussed here, have led research-
ers to take on the challenge of delivering CBTi through the inter-
net. Evolving internet-based communication methods are not 
limited to CBTi and online mental health services are increas-
ingly available, potentially revolutionizing the provision of 
healthcare. Meta-analysis of randomized clinical trials show that 
online treatments are effective for depression, anxiety, and alco-
hol use disorder [45,46]. 
CBTi has many advantages that make it suitable for internet 
delivery. The greatest advantages of internet dCBTi are that it 
does not necessarily limit the audience and patients can be treat-
ed at the time and location of their choosing. In addition, dCBTi 
can improve access to insomnia treatment for people with limit-
ed transportation or poor hospital access. People with psychiat-
ric and medical comorbidities that make it difficult to attend 
conventional CBTi may also consider dCBTi as a better option. 
Internet delivery can free patients from any fear of stigmatization 
associated with accessing a mental healthcare provider. There are 
already numerous books published for self-help CBTi, as well as 
manuals with treatment policies. 
Swedish researchers evaluated the effects of dCBTi for the first 
time [7], reporting that 5 weeks of self-help dCBTi in 109 insom-
nia patients significantly improved total sleep time, total wake 
time in bed, and sleep efficiency. In another study from the Unit-
ed States, in which 45 insomnia patients were randomly assigned 
to the conventional CBTi waitlist or dCBTi, they observed a 16% 
increase in sleep efficiency and 55% decrease in wake time after 
sleep onset in the dCBTi group [47]. A study evaluating the du-
rability of the dCBTi reported that 69.7% of participants main-
tained remission until 1 year after a 6-week dCBTi treatment. 
This result is comparable to the maintenance effect of classical 
face-to-face CBTi [48]. A meta-analysis of 15 randomized, con-
trolled trials of dCBTi showed that dCBTi improves sleep effi-
ciency, insomnia severity, total sleep time, sleep onset latency, 
wake time after sleep onset, and severity of depressive symptoms 
[49,50]. Of the 15 studies included in the analysis, eight were 
6-week programs, two were 5-week, three were 8-week, and two 
were 9-week. This meta-analysis showed similar results to two 
other meta-analyses [51,52] and the calculated publication bias 
was non-significant. 
dCBTi is reportedly convenient and effective for enhancing 
psychological well-being. In an assessment regarding dCBTi use, 
more than 90% of participants responded that dCBTi is conve-
nient, understandable, effective, and useful [53]. In a survey of 
1,711 participants that used dCBTi, researchers found that dCB-
Ti improved insomnia symptoms, as well as daytime symptoms 
such as psychological well-being, sleep-related quality of life, 
mood, fatigue, and work productivity [54]. 
Recently, a patent for a dCBTi digital therapeutic was filed 
with the United States Food and Drug Administration (FDA) for 
use in treating chronic insomnia and depression [55]. The Unit-
ed Kingdom (UK), which provides national healthcare services, 
is already endorsing an internet-based mental health platform as 
part of a stepped-care approach [56]. The UK recommends 
dCBTi as an option for individuals with mild to moderate de-
pression or subthreshold symptoms. In 2018, the U.S. FDA ap-
proved a mobile medical application for treating substance use 
disorder [57]. Thus, the utility of cognitive behavioral therapy via 
the internet has caught public attention. Multidimensional, mul-
tifaceted medical evaluation and treatment through the internet 
has many benefits, including increased convenience for patients, 
reduced cost, and increased access. However, there are still limi-
tations, including the difficulty of individualized treatment, the 
liability of errors in care provision, and appropriateness of diag-
nosis and treatment selection [58].
It is possible for dCBTi to be a pioneer in the digital therapeutics 
market. However, there are clear limitations to the results so far. 
First, most randomization trials were conducted in North America 
and Europe, with few randomization studies in Asia [59]. Limited 
research in Asia, where smartphone and internet usage is preva-
lent, may be related to lack of policy support for telemedicine or a 
high level of regulation. Second, assessment of the effects and limi-
tations of dCBTi have been mostly conducted in middle-aged 
adults. Additional randomized studies of adolescents, older people, 
and people of different cultures and races are essential. Third, most 
study participants had mild to moderate severity of insomnia 
symptoms, so future research on more severe cases is needed. 
Fourth, many studies did not follow up after dCBTi or followed up 
at variable times from 4 to 24 weeks [59-62]. Future studies should 
use more consistent follow-up periods to assess the efficacy of 
dCBTi. 
Zachariae et al. [52] reported an average dropout rate of 24.7% 
in dCBTi studies across 11 randomized controlled trials, which 
is enough to influence results. Also, trials with higher dropout 
rates may show smaller effects and therefore, it is difficult to ex-
clude publication bias [52]. Conventional face-to face CBTi has a 
dropout rate of 14–34%, and participants with a shorter baseline 
total sleep time tended to discontinue treatment early [63]. How-
ever, in a study of 207 dCBTi participants, the dropout rate in-
creased for participants with less severe insomnia who had a to-
tal sleep time of >6 hours [64]. Future research should also be 
conducted regarding adverse effects and placebo effects. Al-
though there is a sufficient lack of studies on conventional CBTi, 
some reports have shown that fatigue/exhaustion, extreme sleep-
iness, reduced motorization/energy, and headache/migraine [65] 
as possible adverse effects of CBTi. 
Finally, the effectiveness of dCBTi compared to existing CBTi 
remains unclear. So far, most studies have compared dCBTi with 
wait-list or sham controls. One study comparing the effects of 
face-to-face group CBTi and dCBTi showed no difference between 
the two groups, not only in primary sleep-related outcomes, but 
also in secondary outcomes, such as adverse events, remission, re-
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sponse rate, depression, and use of sleep medication [66]. Howev-
er, Lancee et al. [67] found that dCBTi had better outcomes than a 
wait-list control group, but worse outcomes than a face-to-face 
CBTi group. Also, participants had a significantly higher prefer-
ence for participating in the face-to-face CBTi group (78%) than 
in the dCBTi group (52%). Similarly, patient adherence was also 
significantly higher in the face-to-face intervention (70%) than in 
dCBTi (50%). Further research should determine where effort 
should be applied to improve dCBTi outcomes.
CONCLUSIONS
This review discusses the history of CBTi as a first-line treat-
ment for insomnia, the current status and limitations of CBTi, 
the efficacy of dCBTi as an alternative therapy, and the future of 
dCBTi. The value of dCBTi extends beyond its usefulness in 
treating insomnia because it is a model for applying digital thera-
peutics to manage stress and improve the quality of life. The de-
velopment of digital therapeutics is well underway, but the chal-
lenge will be to establish criteria for applying, standardizing, and 
assessing treatment.
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